Emergency and Acute Medicine – West Nile Virus




West Nile Virus is a mosquito-borne viral illness caused by an RNA virus from the Flaviviridae family. It is transmitted primarily by infected Culex mosquito during late summer and early fall. Wild birds serve as the main reservoir, and humans become incidental hosts through mosquito bites. Less commonly, transmission can occur via blood transfusion, organ transplantation, or occupational exposure. Since its introduction to the Western Hemisphere in 1999, the virus has become endemic in many regions. After recovery, immunity is generally lifelong, and recurrence is rare.


The clinical presentation of West Nile virus infection varies widely. Approximately 80% of infected individuals are asymptomatic, while about 20% develop a mild, self-limited febrile illness resembling a viral syndrome. A small proportion—roughly 1 in 150 patients—develops neuroinvasive disease, such as meningitis or encephalitis. The incubation period is typically 2–6 days but may extend up to 2–3 weeks, especially in immunocompromised individuals. Severe disease carries a mortality rate of around 7%, with higher risk in elderly patients and those with weakened immune systems.


Patients with mild disease usually present with fever, malaise, headache, anorexia, and sometimes gastrointestinal symptoms such as nausea or diarrhea. These symptoms typically resolve within a week, although fatigue and weakness may persist for several weeks. In more severe cases, neurologic involvement dominates the clinical picture. Patients may develop altered mental status, confusion, seizures, or focal neurologic deficits. A characteristic feature is profound muscle weakness or flaccid paralysis, which can resemble poliomyelitis due to involvement of anterior horn cells. Cranial nerve abnormalities, bulbar dysfunction, and movement disorders may also occur. A transient maculopapular rash may appear on the trunk and extremities.


Diagnosis relies primarily on serologic testing, with the most sensitive method being detection of IgM antibodies using MAC-ELISA in serum or cerebrospinal fluid (CSF). IgM antibodies are usually detectable within the first week of illness and may persist for months. CSF analysis in neuroinvasive disease typically shows lymphocytic pleocytosis, elevated protein, and normal glucose. Imaging such as CT is often normal, while MRI may reveal nonspecific signs of central nervous system inflammation.


Management of West Nile virus is primarily supportive, as there is currently no specific antiviral therapy or vaccine available. Initial stabilization includes airway, breathing, and circulation support, along with seizure precautions if indicated. Treatment consists of intravenous fluids for dehydration, antipyretics for fever, and analgesics for pain. In patients presenting with suspected meningitis or encephalitis, empiric antibiotics and Acyclovir may be initiated until other treatable causes, particularly herpes simplex virus infection, are excluded. No medications—including interferon, ribavirin, or corticosteroids—have proven benefit in controlled studies.


Disposition depends on disease severity. Patients with neurologic involvement, dehydration, advanced age, or immunocompromise require hospital admission, often with neurologic monitoring. Those with mild illness who can tolerate oral intake and have no signs of central nervous system involvement may be discharged with close follow-up. Long-term sequelae such as fatigue, memory impairment, weakness, and headache may persist for weeks to months, and follow-up with a neurologist is often recommended in severe cases.


A key clinical pearl is to always consider other causes of encephalitis, particularly herpes simplex virus, since it is treatable and requires early intervention.

​

Emergency and Acute Medicine: Warts




Warts are benign proliferative lesions of the skin and mucous membranes caused by infection with the Human papillomavirus. The virus infects the basal layer of epithelial tissue, leading to cellular proliferation and increased vascularity, which gives rise to the characteristic verrucous, hyperkeratotic appearance. Warts are extremely common, particularly in children and adolescents, and most resolve spontaneously due to a cell-mediated immune response—about one-third within 6 months, two-thirds within 2 years, and up to 90% within 5 years.


There are several clinical types of warts depending on location and HPV subtype. Verruca vulgaris (common warts) typically occur on the dorsum of the hands, fingers, and around nails and are usually asymptomatic. Verrucae plantaris (plantar warts) occur on weight-bearing areas of the feet such as the heels and metatarsal heads and are often painful due to pressure. Flat (juvenile) warts appear as small, smooth, flesh-colored lesions on sun-exposed areas such as the face, neck, and extremities and may spread with shaving. Anogenital warts, also known as condyloma acuminata, are sexually transmitted and commonly caused by HPV types 6 and 11, while types 16 and 18 are associated with cervical cancer. These lesions are often soft, multiple, and have a cauliflower-like appearance.


Transmission of HPV occurs through direct skin-to-skin contact, indirect contact via contaminated surfaces, or autoinoculation, especially in children who scratch or bite affected areas. The incubation period is variable, ranging from weeks to over a year. In pediatric cases, warts are common, but the presence of anogenital warts should raise concern for possible sexual abuse, particularly in younger children.


Diagnosis is primarily clinical, based on the characteristic appearance of lesions. Common and plantar warts disrupt normal skin lines and may show pinpoint bleeding when scraped. Flat warts are smooth and subtle, while anogenital warts are soft and pedunculated. Laboratory testing is generally unnecessary, although application of acetic acid can help highlight lesions by causing whitening. Biopsy is reserved for atypical, persistent, or suspicious lesions, especially in immunocompromised patients.


Management depends on the type, location, and patient preference. Many warts require no treatment, especially in children, due to high rates of spontaneous resolution. For cutaneous warts, first-line therapy includes topical salicylic acid, typically 17% over-the-counter or up to 70% prescription strength, applied after soaking the wart for 10–20 minutes, left on overnight, and followed by gentle debridement. Treatment is repeated regularly and may take weeks to months. Another simple method is duct tape occlusion therapy, which may be particularly useful in children.


For anogenital warts, treatment options include patient-applied therapies such as Imiquimod (5% cream applied three times per week for up to 16 weeks) and Podofilox (0.5% solution or gel applied twice daily for 3 days followed by 4 days off, repeated up to 4 cycles). Provider-administered treatments include podophyllin (10–25% weekly application), trichloroacetic acid (80–90% weekly for 6–10 weeks), and cryotherapy with liquid nitrogen every 1–2 weeks. These treatments require caution, especially in pregnancy or when applied to sensitive mucosal areas.


Preventive strategies include vaccination with Gardasil, which protects against HPV types 6, 11, 16, and 18 and is given as a 3-dose series over 6 months. This vaccine significantly reduces the risk of genital warts and HPV-related cancers. Another vaccine, Cervarix, targets oncogenic strains associated with cervical cancer.


Most patients can be managed as outpatients, but referral to dermatology or gynecology is appropriate for treatment-resistant cases, atypical lesions, or anogenital involvement. Follow-up is important to ensure treatment response and monitor for recurrence. Patients should be advised to return if lesions change, become painful, or fail to improve.


A key clinical pearl is that HPV vaccines do not protect against all HPV types, and patients may still develop warts despite vaccination. Additionally, clinicians should always consider the broader clinical context, including the possibility of immunosuppression or, in pediatric cases with anogenital lesions, safeguarding concerns.

​

Emergency and Acute Medicine: Warfarin Complications




Warfarin is a widely used oral anticoagulant that works by inhibiting vitamin K–dependent clotting factors (II, VII, IX, and X), thereby affecting both the extrinsic and common coagulation pathways. It is commonly prescribed for conditions such as venous thromboembolism, atrial fibrillation, and prosthetic heart valves. Its therapeutic effect is monitored using the International Normalized Ratio, with typical target ranges of 2–3 or 2.5–3.5 depending on indication. However, due to its narrow therapeutic window and numerous interactions, warfarin is associated with significant complications, most notably bleeding.


Bleeding is the most common complication, occurring in up to 15% of patients annually, with major bleeding events in about 5% and fatal bleeding (most often Intracranial hemorrhage) in less than 1%. The risk of bleeding increases significantly when the INR exceeds 4. Patients may present with a wide spectrum of symptoms, ranging from occult bleeding to life-threatening hemorrhage involving the gastrointestinal tract, central nervous system, or retroperitoneum. Conversely, subtherapeutic INR levels may result in breakthrough thrombosis, particularly in high-risk patients.


Several factors predispose patients to unstable INR levels and complications, including advanced age (>75 years), comorbidities such as hypertension, diabetes, renal or liver disease, malignancy, and hyperthyroidism. Drug and dietary interactions are especially important: antibiotics, Amiodarone, NSAIDs, and certain herbal supplements (e.g., ginkgo, garlic) can increase INR, while drugs like Rifampin, carbamazepine, and high vitamin K intake can decrease it. Warfarin is contraindicated in pregnancy due to its teratogenic effects.


A unique complication is warfarin-induced skin necrosis, which typically occurs within the first week of therapy and is associated with protein C deficiency. It presents as painful skin lesions that progress to necrosis with central eschar formation. Limb gangrene may also occur due to venous thrombosis. In cases of overdose or ingestion of long-acting anticoagulants (e.g., “superwarfarins” found in rodenticides), patients may initially be asymptomatic but develop prolonged coagulopathy requiring extended monitoring.


Evaluation requires a thorough history, including indication for anticoagulation, recent dose changes, medication interactions, and prior INR values. Physical examination should focus on signs of bleeding (e.g., ecchymosis, pallor, hypotension) and subtle neurologic changes suggestive of intracranial bleeding. Laboratory testing includes PT/INR, CBC, renal and liver function tests, and type and crossmatch if bleeding is suspected. Imaging, particularly CT scans, should be obtained liberally to detect occult bleeding, especially in trauma patients or those with neurologic symptoms.


Management depends on the INR level and presence of bleeding. For patients with INR <5 and no bleeding, the next dose may be held or reduced with close monitoring. For INR 5–9 without bleeding, holding warfarin and administering Vitamin K1 at 1–5 mg PO may be appropriate, especially in high-risk patients. For INR ≥9 without bleeding, vitamin K 2.5–5 mg PO is recommended. In cases of serious or life-threatening bleeding (any INR), immediate reversal is required with vitamin K 10 mg IV (slow infusion over 10–30 minutes) along with clotting factor replacement.


Rapid reversal is best achieved using Prothrombin complex concentrate, which contains clotting factors II, VII, IX, and X. Dosing is weight- and INR-dependent: 25 U/kg for INR 2–3.9, 35 U/kg for INR 4–5.9, and 50 U/kg for INR ≥6. PCC is preferred in cases of intracranial hemorrhage, massive bleeding, or when volume overload is a concern. Alternatively, Fresh frozen plasma may be used, typically 3–4 units (≈1 L), though it carries risks such as fluid overload and slower INR correction. In refractory or complex cases, adjuncts such as factor VIIa may be considered.


Disposition depends on severity. Patients with active bleeding, especially involving the CNS, GI tract, or retroperitoneum, require admission and often ICU-level care. Stable patients with asymptomatic supratherapeutic INR and reliable follow-up may be discharged with close monitoring. Follow-up within 24–48 hours for repeat INR testing is essential.


A key clinical pearl is to maintain a low threshold for imaging in anticoagulated patients, even after minor trauma, as serious bleeding may occur without obvious symptoms. Additionally, vitamin K should generally not be given for INR <5 without bleeding, and IV vitamin K should be reserved for severe cases due to the rare but serious risk of anaphylaxis.

​

​Emergency and Acute Medicine: Von Willebrand Disease


Von Willebrand Disease is the most common inherited bleeding disorder and results from either a deficiency or dysfunction of von Willebrand factor, a key protein involved in hemostasis. vWF plays two major roles: it mediates platelet adhesion to the vascular endothelium and serves as a carrier protein for Factor VIII. The disease affects approximately 1–2% of the general population and is usually inherited, though acquired forms can occur.


There are three major types of vWD. Type 1, the most common (about 70%), is a quantitative deficiency of vWF and is typically inherited in an autosomal dominant pattern, with symptoms ranging from mild to moderate bleeding. Type 2 involves qualitative defects in vWF function and includes several subtypes (2A, 2B, 2M, 2N), with type 2N characterized by reduced binding to factor VIII, leading to more significant coagulopathy. Type 3 is rare, inherited in an autosomal recessive pattern, and represents a severe deficiency or absence of vWF, resulting in serious bleeding manifestations. In addition to genetic causes, acquired vWD may occur due to conditions such as malignancies, autoimmune diseases, hypothyroidism, or certain medications.


Clinical presentation varies widely depending on the type and severity of the disorder. Many patients with type 1 or mild type 2 disease may be asymptomatic, while those with more severe forms present with mucocutaneous bleeding, including easy bruising, recurrent epistaxis, gum bleeding, and menorrhagia. Gastrointestinal bleeding, prolonged bleeding after procedures, and postoperative hemorrhage may also occur. In more severe cases, such as type 3 disease, patients may develop deep tissue bleeding and hemarthroses, resembling hemophilia. A detailed history often reveals a family history of bleeding and recurrent minor bleeding episodes, especially in pediatric and adolescent populations.


Physical examination is often normal, although findings may include ecchymoses, hematomas, or joint swelling in more severe cases. Special considerations include pregnancy, during which vWF levels may increase temporarily, often leading to fewer bleeding complications; however, levels drop postpartum, increasing the risk of delayed bleeding. In children, clinicians must always consider nonaccidental trauma when unexplained bruising or bleeding is present.


Diagnosis relies on laboratory evaluation. Platelet counts and morphology are typically normal, and prothrombin time (PT) is usually normal. Partial thromboplastin time (PTT) may be mildly prolonged due to reduced factor VIII levels. Specific tests include measurement of vWF antigen and activity, particularly the ristocetin cofactor assay, which evaluates vWF function through platelet agglutination. Bleeding time may be prolonged in more severe types but is less commonly used כיום due to poor reproducibility.


Management focuses on controlling bleeding and correcting the underlying defect. Initial stabilization includes standard resuscitation measures with fluids and blood products as needed, along with direct pressure to bleeding sites. The cornerstone of therapy for mild to moderate disease is Desmopressin, which promotes the release of endogenous vWF and increases factor VIII levels. It is administered at 0.3 μg/kg IV or subcutaneously (maximum 20 μg), or 300 μg intranasally (150 μg if <50 kg), with peak effect occurring within 30–60 minutes and lasting 6–8 hours. It is most effective in type 1 disease, variably effective in type 2, and not useful in type 3.


For severe bleeding or type 3 disease, vWF replacement therapy is required, typically using Humate-P at doses of 20–40 units/kg IV. Antifibrinolytic agents such as Tranexamic acid (20–25 mg/kg PO or IV every 8 hours) and Aminocaproic acid (50–60 mg/kg PO or IV every 4–6 hours) are useful adjuncts, particularly for mucosal bleeding. Although Cryoprecipitate and Fresh frozen plasma may contain vWF, they are generally reserved for life-threatening situations when safer products are unavailable due to infection risk. Patients should avoid antiplatelet medications such as NSAIDs, which can worsen bleeding.


Disposition depends on severity. Patients with significant or ongoing bleeding, especially those requiring IV therapy, should be admitted and managed in consultation with hematology. Those with controlled bleeding and reliable follow-up may be discharged with clear instructions. Long-term management includes hematology referral for definitive diagnosis, planning before surgical procedures, and education regarding bleeding risk.


A key clinical pearl is that patients may not know their specific subtype of bleeding disorder, and in emergency situations with significant bleeding, empiric treatment (e.g., FFP or vWF-containing products) may be necessary while awaiting definitive diagnosis.

Emergency and Acute Medicine: Vomiting (Pediatric)




Pediatric vomiting is a forceful, coordinated expulsion of gastric contents through the mouth, involving the phases of nausea, retching, and emesis. During vomiting, there is sustained contraction of the abdominal muscles and diaphragm, while the pylorus and antrum contract simultaneously. Unlike adults, vomiting in children—especially neonates and infants—requires a high index of suspicion for serious pathology, as it may be the first sign of life-threatening disease.


The etiology of pediatric vomiting is broad and age-dependent, encompassing gastrointestinal, metabolic, neurologic, infectious, and feeding-related causes. Gastrointestinal causes include conditions such as Hypertrophic pyloric stenosis, Intussusception, and Midgut volvulus, all of which may lead to obstruction and require urgent intervention. Metabolic causes include inborn errors of metabolism and diabetic ketoacidosis, while neurologic causes include intracranial hemorrhage, tumors, or hydrocephalus. Infectious etiologies such as gastroenteritis, urinary tract infections, pneumonia, and sepsis are also common. Feeding-related issues, including overfeeding or milk allergy, are particularly relevant in infants.


Clinical presentation varies depending on the underlying cause, but assessment of vomiting characteristics is critical. Nonbilious vomiting suggests obstruction proximal to the pylorus, whereas bilious (green) vomiting indicates obstruction distal to the ampulla of Vater and is a surgical emergency until proven otherwise. Bloody vomiting may indicate upper gastrointestinal bleeding, while “coffee-ground” emesis reflects digested blood. A feculent odor suggests distal bowel obstruction or peritonitis. Projectile vomiting in a 2–6 week old infant is classic for hypertrophic pyloric stenosis, while sudden onset vomiting with abdominal distention and systemic illness may suggest volvulus or intussusception.


On physical examination, clinicians should assess hydration status, vital signs, and overall appearance, as children can deteriorate rapidly. Signs such as tachycardia, poor perfusion, altered mental status, or shock indicate severe illness. Abdominal examination may reveal distention, tenderness, masses, or peritoneal signs suggesting obstruction or perforation. Additional examination should include evaluation of the genitourinary system (e.g., testicular torsion) and neurologic status.


The diagnostic workup is guided by clinical suspicion and aimed at excluding life-threatening causes. Laboratory studies may include glucose, electrolytes, and infection markers (CBC, cultures). Imaging plays a key role: abdominal radiographs can identify obstruction or perforation, while ultrasound is particularly useful for diagnosing pyloric stenosis and intussusception. CT scans may be required for complex cases such as appendicitis or masses. In some cases, nasogastric tube placement can aid in diagnosis and management by assessing gastric contents.


Management begins with initial stabilization, including airway, breathing, and circulation assessment. Fluid resuscitation with isotonic saline (0.9% NS) is essential, especially in dehydrated or hypovolemic children, while cautiously considering conditions such as increased intracranial pressure. Bedside glucose testing is important to detect hypoglycemia. Gastric decompression with a nasogastric or orogastric tube may be required in cases of obstruction or persistent vomiting. Treatment then focuses on identifying and addressing the underlying cause, with early surgical consultation when an acute abdomen is suspected. Antibiotics should be initiated if infection or peritonitis is present.


Antiemetic therapy may be used once serious causes have been excluded or addressed. First-line therapy includes Ondansetron, given at 0.1 mg/kg per dose (typically 4–8 mg) IV or PO every 6 hours. Second-line options include Metoclopramide at 0.1 mg/kg per dose PO every 6 hours, Prochlorperazine at 0.1 mg/kg per dose IV, IM, or PR every 6 hours, and Promethazine at 0.25 mg/kg per dose PO, PR, or IM every 6 hours. These medications should be used cautiously due to potential side effects, especially in younger children.


Disposition depends on the child’s clinical status and underlying cause. Admission is required for unstable vital signs, dehydration, inability to tolerate oral intake, or suspected serious pathology. Children may be discharged if they are stable, able to tolerate fluids, and serious causes have been excluded, with clear instructions given to caregivers regarding warning signs such as persistent vomiting, abdominal distention, decreased urine output, fever, lethargy, or behavioral changes.


A critical clinical pearl is that bilious vomiting in neonates is an emergency and should be assumed to represent intestinal obstruction (e.g., malrotation with volvulus) until proven otherwise. Additionally, clinicians must always consider non-gastrointestinal causes of vomiting, including neurologic, metabolic, and toxicologic etiologies, to avoid missing potentially life-threatening conditions.

​

​

Emergency and Acute Medicine: Volvulus




Volvulus is an axial twisting of a segment of the gastrointestinal tract around its mesentery, resulting in partial or complete bowel obstruction. This twisting can compromise venous outflow and eventually arterial inflow, leading to bowel ischemia, gangrene, and possible perforation. It is a life-threatening surgical emergency, particularly when vascular compromise is present. Volvulus accounts for approximately 10–15% of colonic obstructions and is most commonly seen in the cecum and sigmoid colon. Cecal volvulus typically affects younger adults due to congenital mobility of the cecum, whereas sigmoid volvulus is more common in elderly, institutionalized patients with chronic constipation, neurologic disease, or psychiatric illness. In children, especially neonates, midgut volvulus occurs due to congenital malrotation and often presents early with bilious vomiting.


The clinical presentation varies depending on the location and severity but generally reflects bowel obstruction. Patients commonly report colicky abdominal pain, abdominal distention, obstipation, nausea, and vomiting. The onset may be acute or more insidious, particularly in sigmoid volvulus, where symptoms may recur intermittently over weeks or months. In contrast, midgut volvulus in infants presents abruptly with bilious vomiting and abdominal pain. Signs of bowel ischemia or gangrene include fever, tachycardia, hypotension, peritoneal signs (guarding, rebound), hematochezia, and shock, indicating advanced disease and the need for immediate surgical intervention.


Diagnosis relies on clinical suspicion supported by imaging. Plain abdominal radiographs may demonstrate characteristic findings such as the “coffee bean” sign in sigmoid volvulus or a displaced, dilated cecum. However, CT imaging is the preferred modality in adults and may reveal the classic “whirl sign” of twisted mesenteric vessels. In pediatric patients, an upper gastrointestinal contrast study is the most sensitive initial test and may show a “corkscrew” appearance of the twisted bowel. A barium enema may demonstrate a “bird’s beak” deformity, though it must be used cautiously due to the risk of perforation.


Initial management focuses on rapid stabilization. Patients should be kept nil per os (NPO), and aggressive fluid resuscitation should be initiated with isotonic fluids such as 0.9% saline (2 L bolus in adults or 20 mL/kg in children). A nasogastric tube should be inserted for decompression, and electrolyte abnormalities should be corrected. Early consultation with surgery and gastroenterology is essential. Definitive management depends on the type of volvulus and the patient’s condition. In stable patients with sigmoid volvulus, endoscopic decompression may be attempted and is often successful, although recurrence is common and elective surgical resection is usually required. In unstable patients or those with cecal volvulus, urgent surgical intervention with bowel resection is necessary. In children with midgut volvulus, emergency surgery (Ladd procedure) must be performed promptly to prevent bowel necrosis.


Medication management is supportive and aimed at preventing or treating complications such as infection, ischemia, or perforation. Broad-spectrum intravenous antibiotics should be administered when there is concern for sepsis or bowel compromise. Options include Ampicillin-sulbactam at a dose of 3 g IV every 6 hours (pediatric: 100–200 mg/kg/day divided every 6 hours), or Cefoxitin at 2 g IV every 6 hours (pediatric: 80–160 mg/kg/day divided every 6 hours). Another commonly used regimen is Ceftriaxone 1–2 g IV every 12–24 hours combined with Metronidazole 500 mg IV every 8 hours (pediatric metronidazole: 30 mg/kg/day divided every 6 hours). Alternatively, Piperacillin-tazobactam may be used at 3.375–4 g IV every 4–6 hours (pediatric: 200–300 mg/kg/day of the piperacillin component divided every 6–8 hours). These regimens provide essential coverage against gram-negative and anaerobic organisms commonly involved in bowel infections.


All patients with suspected volvulus require hospital admission and urgent surgical evaluation, as there are no safe discharge criteria. Delayed diagnosis significantly increases morbidity and mortality, particularly if bowel ischemia develops. Early recognition, aggressive resuscitation, appropriate antibiotic therapy, and timely surgical intervention are critical to improving outcomes and preventing life-threatening complications.

​

Emergency and Acute Medicine: Vitreous Hemorrhage




Vitreous Hemorrhage is the presence of blood within the vitreous cavity of the eye and is considered a secondary diagnosis, meaning that identifying the underlying cause is essential for proper management. It most commonly results from retinal vessel disruption due to vitreous separation, trauma, or spontaneous bleeding from neovascularization, particularly in patients with diabetes mellitus.


The causes of vitreous hemorrhage are varied and include both traumatic and nontraumatic conditions. Trauma may be blunt or penetrating, leading to direct vessel rupture. Nontraumatic causes include proliferative retinopathies (especially diabetic retinopathy), retinal tears or detachments, retinal vein occlusion, sickle cell disease, and age-related macular degeneration. Less common causes include intraocular tumors and intracranial hemorrhage such as Terson syndrome. In pediatric patients, important considerations include prematurity, congenital retinal disorders, and nonaccidental trauma such as shaken-baby syndrome.


Clinically, patients typically present with sudden, painless, unilateral visual disturbance, ranging from mild blurring to significant vision loss. They often describe floaters, cobwebs, or a hazy visual field, sometimes accompanied by flashing lights if there is associated retinal traction. On examination, a key finding is loss of the red reflex and inability to visualize the fundus, which strongly suggests vitreous hemorrhage. A mild afferent pupillary defect may also be present depending on severity.


Evaluation requires a thorough ocular examination, including slit-lamp assessment, tonometry, and dilated fundoscopic examination. When the fundus cannot be visualized, B-scan ultrasonography is essential to assess for serious underlying pathology such as retinal detachment or intraocular tumor. Additional laboratory tests, such as complete blood count and coagulation studies, may be performed if a systemic cause is suspected. Imaging like CT may be necessary in cases of trauma to exclude intraocular foreign bodies.


Management in the emergency setting is primarily supportive. Patients should be advised to rest with the head of the bed elevated to allow blood to settle inferiorly and improve vision. Activities that increase intraocular pressure, such as heavy lifting or straining (Valsalva), should be avoided. Medications that impair clotting, such as NSAIDs and anticoagulants, should also be avoided unless medically necessary. There are no specific emergency medications required for vitreous hemorrhage itself; treatment is directed at the underlying cause.


Definitive management is guided by ophthalmology and may include laser photocoagulation or cryotherapy for proliferative vascular disease, surgical repair for retinal detachment, or vitrectomy if the hemorrhage does not resolve or is associated with complications such as neovascularization or glaucoma. Urgent ophthalmologic consultation within 24–48 hours is essential, even in seemingly mild cases, to prevent missed vision-threatening conditions.


A critical point is that vitreous hemorrhage may mimic or coexist with other serious conditions such as retinal detachment or vascular occlusions. Therefore, prompt evaluation and follow-up are necessary to prevent permanent visual impairment.

​

Emergency and Acute Medicine: Visual Loss


Visual Loss refers to any decrease in visual function, including reduced visual acuity, visual field defects, or blurred vision. It is a high-stakes emergency presentation because causes range from benign refractive errors to immediately vision-threatening or life-threatening conditions such as stroke or vascular occlusion. The etiology is broad and includes ophthalmologic (corneal, retinal, optic nerve), traumatic, neurologic, cardiovascular, infectious, immunologic, endocrine, and toxic causes.


A key step in evaluation is categorizing the visual loss based on time course, pain, and laterality. Transient visual loss lasting minutes is often due to ischemia, such as amaurosis fugax (a form of transient ischemic attack), while episodes lasting hours may suggest migraine or hemodynamic instability. Persistent visual loss can be painless—seen in retinal detachment, vascular occlusion, or optic neuritis—or painful, as in acute angle-closure glaucoma, corneal injury, or uveitis. Monocular vision loss typically indicates pathology anterior to the optic chiasm (eye or optic nerve), whereas binocular loss suggests lesions posterior to the chiasm, such as occipital stroke or mass lesions.


Clinical evaluation requires a thorough history and focused eye examination. Important historical features include onset (sudden vs gradual), presence of pain, trauma, associated neurologic symptoms, and visual phenomena such as floaters or flashing lights. Physical examination must include visual acuity (always documented), pupillary responses (looking for afferent pupillary defect), visual fields, extraocular movements, intraocular pressure measurement, and fundoscopic exam. Systemic examination may reveal clues such as carotid bruits (embolic source) or temporal artery tenderness suggestive of Giant Cell Arteritis.


Three conditions require immediate recognition and treatment within minutes to prevent permanent vision loss. Central Retinal Artery Occlusion presents with sudden, painless monocular vision loss and a classic “cherry-red spot” on fundus exam. Management includes urgent ophthalmology consultation, ocular massage, and reduction of intraocular pressure (e.g., acetazolamide) to dislodge the embolus. Chemical eye burns demand immediate and copious irrigation (at least 30 minutes) to normalize ocular pH—this should begin even before full evaluation. Acute Angle-Closure Glaucoma presents with painful vision loss, a red eye, mid-dilated pupil, and elevated intraocular pressure; treatment involves rapid pressure reduction using topical and systemic agents (e.g., beta-blockers, acetazolamide, pilocarpine).


Additional investigations depend on suspected etiology. Laboratory testing (e.g., ESR) is crucial when giant cell arteritis is suspected, while imaging such as CT, MRI, or vascular studies (carotid ultrasound) may be required for neurologic or embolic causes. A dilated fundus examination is essential for evaluating posterior segment pathology. In cases of suspected embolic disease, cardiac and carotid evaluation is necessary to prevent future strokes.


Management is directed at the underlying cause, with early ophthalmology consultation for any uncertain or severe case. Admission is required for serious conditions such as orbital cellulitis, cavernous sinus thrombosis, ruptured globe, or associated neurologic or vascular disease. Patients may be discharged only if the diagnosis is clear, stable, and not progressive, with appropriate follow-up arranged.


A critical principle in emergency care is that visual acuity must be documented in every patient with eye complaints, and any sudden vision loss should be treated as an emergency until proven otherwise. Missing time-sensitive diagnoses like retinal artery occlusion or glaucoma can result in irreversible blindness, making rapid recognition and intervention essential.

Emergency and Acute Medicine: Management of Violence 




Management of Violence in Emergency Department is a critical component of emergency medicine, as EDs are high-risk environments for aggressive and violent behavior. Contributing factors include overcrowding, prolonged waiting times, substance intoxication, psychiatric illness, and patients arriving in police custody. Individuals with a prior history of violence, poor impulse control, or intoxication are at particularly high risk. Importantly, violence may stem not only from psychiatric conditions such as psychosis or mania but also from underlying medical issues like hypoglycemia, hypoxia, infections, intoxication, withdrawal states, or neurologic disorders.


Early recognition of escalating behavior is essential for prevention. Initial warning signs include loud speech, agitation, pacing, and clenched fists, while more concerning features include threatening language, irrational behavior, and invasion of personal space. A thorough assessment should include history of prior violence, substance use, medical and psychiatric conditions, and current triggers. Clinicians must remain vigilant for medical causes of agitation, especially in patients over 40 years old without a psychiatric history or those with abnormal vital signs or focal neurologic findings.


Management begins with ensuring safety for both staff and patients. Environmental strategies include visible security presence, controlled access, removal of potential weapons, and clear protocols. When approaching a potentially violent patient, clinicians should not act alone, maintain a safe distance, keep an open exit path, and use a calm, non-confrontational approach. Verbal de-escalation is always the first-line intervention—this involves acknowledging the patient’s concerns, setting clear boundaries, and offering choices to reduce agitation.


If de-escalation fails, escalation to seclusion or restraint may be necessary. Physical restraints should follow institutional protocols, with careful documentation of indications, prior attempts at de-escalation, and ongoing monitoring. Positioning is important—supine for evaluation or lateral if aspiration risk exists—and airway safety must always be maintained. Chemical restraint is often required in conjunction with physical restraint, using medications such as antipsychotics (e.g., haloperidol) and/or benzodiazepines (e.g., lorazepam). The choice depends on the underlying cause: benzodiazepines are preferred in hyperadrenergic states (e.g., stimulant intoxication), while antipsychotics are commonly used in primary psychiatric agitation. Combination therapy is frequently effective.


Ongoing monitoring is crucial after restraint, particularly for complications such as respiratory depression, QT prolongation, or neuroleptic malignant syndrome. Vulnerable populations—including the elderly and those with medical comorbidities—require lower medication doses and closer observation. A key principle is to treat the underlying cause whenever possible, rather than focusing solely on behavioral control.


Disposition depends on the etiology. Patients with medical causes require admission for further management, while those with psychiatric illness may need inpatient psychiatric care, including involuntary admission if they pose a risk to themselves or others. Safe discharge requires stabilization, reassessment (especially if intoxicated), and clear follow-up plans. Clinicians must also be aware of legal responsibilities, including duty to warn or protect others when credible threats are identified.


A critical clinical takeaway is that not all violent behavior is psychiatric in origin—failure to identify an underlying medical cause can lead to significant morbidity. Effective management requires a structured, stepwise approach prioritizing safety, de-escalation, appropriate restraint, and treatment of the root cause.

​